JonesTrading analyst Soumit Roy maintained a Buy rating on Cullinan Management today and set a price target of $34.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Soumit Roy has given his Buy rating due to a combination of factors that highlight the potential of Cullinan Management’s zipalertinib in treating challenging cases of EGFR mutated NSCLC. The recent data presented at ESMO demonstrated significant efficacy of zipalertinib in patients with active brain metastases, with an intracranial objective response rate of 31%. This is particularly noteworthy as these patients are typically harder to treat, having undergone multiple prior therapies that compromise the blood-brain barrier, allowing for better CNS penetration of the drug.
Furthermore, the potential for accelerated approval of zipalertinib in the 2L+ setting is supported by its promising performance in the REZILIENT2 cohort, which could lead to its use in combination with chemotherapy in first-line settings. Despite competition from other treatments like firmonertinib, zipalertinib’s ability to address a more difficult patient population and its comparable safety profile make it a strong candidate for second-line therapy. This strategic positioning, coupled with the unmet need in the market, underpins the Buy rating.
According to TipRanks, Roy is an analyst with an average return of -18.5% and a 24.80% success rate. Roy covers the Healthcare sector, focusing on stocks such as Protara Therapeutics, CervoMed, and Cullinan Management.
In another report released on October 13, Wedbush also reiterated a Buy rating on the stock with a $23.00 price target.